Tang Capital Management’s Cytokinetics CYTK Stock Holding History

Tang Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$5.5M	–	110
2025 Q3	$5.5M	Hold	100,000	–	–	0.21%	93
2025 Q2	$3.3M	Hold	100,000	–	–	0.17%	104
2025 Q1	$4.02M	Hold	100,000	–	–	0.22%	82
2024 Q4	$4.7M	Hold	100,000	–	–	0.31%	75
2024 Q3	$5.28M	Hold	100,000	–	–	0.38%	72
2024 Q2	$5.42M	Hold	100,000	–	–	0.55%	55
2024 Q1	$7.01M	Sell	100,000 -10,000	-9%	-$773K	0.73%	48
2023 Q4	$9.18M	Buy	+110,000	New	+$3.98M	0.85%	32
2023 Q1	–	Sell	-110,000	Closed	-$5.04M	–	113
2022 Q4	$5.04M	Buy	+110,000	New	+$4.73M	0.73%	36

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Tang Capital Management's CYTK Position: Q4 2025 in Review

Tang Capital Management sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 100,000 shares — an estimated $5.5M sold.

Tang Capital Management first reported a position in CYTK in Q4 2022 and held it in 9 quarters. The position peaked at $9.18M in Q4 2023. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

Tang Capital Management reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 100,000 Cytokinetics shares in Q4 2025, an estimated $5.5M.
Tang Capital Management first reported a position in Cytokinetics in Q4 2022 and held it in 9 quarters.
Tang Capital Management's Cytokinetics position peaked at $9.18M in Q4 2023.
430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.